Perfusion-based biomanufacturing is gaining momentum across the biopharmaceutical industry as sponsors seek higher output, improved product quality and manufacturing flexibility without expanding facility footprints. Recent advances center on technology updates in perfusion media, cell retention and real-time process analytics. Industry sources cite how continuous harvesting at high viable cell densities can increase productivity per bioreactor volume and reduce variability in quality attributes such as glycosylation and aggregation. Advances in alternating tangential flow (ATF) and tangential flow filtration (TFF) aim to reduce filter fouling, while monitoring tools—like Raman spectroscopy and soft sensors—support robustness in longer runs. Despite the progress, the report notes that perfusion remains operationally complex, and the next wave of adoption depends on performance, cost and reliability at commercial scale.